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Summary 
A consensus conference involving health professionals active in the management of facet joint pain 
along with lay representatives to discuss and agree five design considerations for a feasibility study in 
advance of a clinical trial of facet joint injections. The design considerations concerned: diagnosis, the 
process of facet joint injection, best usual care, size of signal (minimal important change/difference) and 
sub-groups for analysis. The consensus conference was provided with systematic evidence reviews on 
each of these design considerations, opportunity for discussion in small groups and a series of nominal 
group technique rankings. Of the 50 attendees only 3 dissociated themselves from the final consensus 
outcome. Post conference clarifications were undertaken by email. The design of the feasibility study 
protocol was altered to incorporated consensus findings and is available at:  
http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0019/130654/PRO-11-31-01.pdf 
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Background 
The Facet Injection study (FIS) is one of two studies commissioned in 2014 (NIHR, HTA) to assess the 
clinical- and cost-effectiveness of facet-joint injections in selected patients with non-specific low back 
pain. The other project is comparing facet joint injections with local anaesthetic and steroid to a sham 
procedure in people with positive diagnostic test for facet joint disease. (See http://www.controlled-
trials.com/ISRCTN12191542/12191542). In our study we will explore the feasibility of running a 
randomised controlled trial to test the hypothesis that, for people with suspected facet joint pain 
contributing to persistent low back pain, adding the option of facet joint injections, with local 
anaesthetic and corticosteroids, to best usual non-invasive care available from the NHS is clinically and 
cost-effective.  
To ensure that the FIS protocol was robust and informed by current evidence and expert opinion, was 
acceptable to the academic community and practicing clinicians and reflected NHS practice a four stage 
process was adopted. First, the FIS team identified key design considerations that are of vital 
importance for the production of robust and acceptable evidence on an implementable facet joint 
injection programme. Second, an evidence review of each design consideration was conducted using 
systematic methodology. Third, an evidence document was prepared that contextualised the pragmatic 
FIS, outlined the methodological challenges of designing a credible pragmatic trial and presented the 
outputs from the evidence reviews. Fourth, using the evidence document as a delegate pack the FIS 
design considerations were considered by a consensus conference of clinicians, experts, academics and 
patients.  
This report describes the FIS (Facet injection Study) design considerations and their implications for the 
study, the consensus conference process, its results and discuss how this has helped to shape the study 
protocol. The methods and results sections are divided into pre conference, conference and post 
conference phases.  
The Facet Injection study team identified five design considerations: 
1. Diagnosis 
2. Process of facet joint injection 
3. Management/rehabilitation of those with of those with facet joint pain (Best Usual care) 
4. Size of signal (Minimal important change/difference) 
5. Sub-groups for analysis 
Figure 1 provides an overview of the whole process  
Methods 
Pre conference: 
The research team undertook scoping reviews of clinical practice guidelines, empirical studies and 
related literature and discussed project design.. Discussions included pain clinicians, physical therapists 
and lay representatives. From this process key design considerations for this study were identified.  
These design considerations were taken forward for discussion at a consensus conference. To inform 
consensus development an evidence document was produced based on systematic reviews of current 
literature.  
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Figure 1. Facet Injection Study Protocol Development Process 
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The conference was organised to cover a whole day (between 9am and 4.30) at a conference centre at 
the University of Warwick, UK. Invitations to the conference were distributed through relevant 
professional organisations and lay groups. There was no charge for attendance and out-of-pocket travel 
expenses were paid.  
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Evidence documents were sent to all those who registered to attend approximately one week before 
the conference. 
Consensus conference: 
The conference included discussion of the design considerations and, to reach consensus, the use of 
nominal group technique (NGT) as this allows for confidential ranking of options. As noted earlier we 
had five key design considerations for discussion at the conference. The morning consisted of four 
sessions. The first was an introduction to remind all participants of the design considerations and 
evidence and to explain the consensus process. This was followed by three one hour long small group 
discussions. In each of the three morning sessions the participants were divided into five small groups 
for discussion (in separate rooms) along with the first round of NGT. The three ‘operational’ design 
considerations (diagnosis, injection and best usual care) were discussed by four differently constituted 
groups.  Minimal important change was discussed by two groups and sub-group analysis one. Prior to 
the day all delegates were randomly assigned to small group discussion stratified by profession 
(approximately 10-12 per group). This ensured that all delegates were able to participate in three 
different discussion groups during the morning. Delegates were assigned to a group but would find they 
were with different people in each of the three groups they attended. The afternoon, plenary, session 
brought together results from the morning sessions for further discussion and ranking through NGT. All 
sessions were audio recorded to allow clarification of what happened in the groups during analysis.   
The small groups had a trained facilitator, a scribe (Medical Student) and a subject expert from the 
research team. The expert DID NOT participate in the discussions but was there to aid with technical 
points. Discussions centred on the particular design consideration often with the suggested ‘protocol’ as 
a starting point. In the groups on injection and best usual care, due to the large number of topics to be 
covered, delegates were asked if each of the suggested techniques was acceptable (i.e. not necessarily 
what they themselves would do or advise but an acceptable method/technique). Those where there 
was lack of agreement in the group were discussed. Ranking and re-ranking was used when required to 
come to a conclusion for the group at the end of the session.  
During the lunch break all of the morning sessions were collated and results from the small groups were 
taken forward to the afternoon plenary session. Each of the topics was presented and discussed. 
Ranking was used to finalise results where there was no consensus emerged from the small groups. 
Post Conference: 
All results were carefully checked and verified from both the morning and afternoon sessions. A small 
number of errors were found and the team contacted relevant groups of delegates via email to clarify 
and reach a consensus on these items.  
The results of the day were used to inform the writing of the protocol for the facet injection study.   
 
 
 
 
  
8 
© FIS Consensus Conference Report 14 February 2015   
The University of Warwick, Version 1   
Results 
Pre Conference: 
A full evidence document was produced (78 pages plus) for each delegate and distributed electronically 
before the day and provided in hardcopy on the day. This included tabulated results of the searches, 
brief summaries and in several cases suggested ‘protocols’. Note: a copy of the evidence document can 
be requested from the FIS team at FIS@warwick.ac.uk (this document is copyright). 
For each design consideration a question was posed in the evidence document for consideration at the 
consensus conference. These were: 
• Diagnosis 
o What is the best choice of clinical assessment to identify patients with suspected facet 
joint pain? 
• Injection technique 
o What is the agreed technique for the injection of facet joints? 
• Best usual Care 
o What is the optimal conservative management/rehabilitation for patients with low back 
pain where facet joints have been identified as a contributing source of symptoms? 
• What is the difference in magnitude of response between treatment and control groups 
that should be considered large enough to establish the scientific or therapeutic importance 
of the results? 
o What is the minimal between-group difference in change scores necessary for Facet 
Joint Injection(s) to be considered worthwhile? 
o At 3-months, should we be seeking a mean between-group difference in change scores 
that is smaller / the same / or larger than that observed for the trials of manual 
therapy? 
o Informed by the MID-units calculated for the trials of manual therapy (supporting 
evidence), at 3-months should we be seeking a small (<0.5), medium (0.5-1.0) or large 
(>1.0) MID-unit as proof of important difference?  
o What magnitude of reduction in pain after the injection constitutes immediate pain 
relief?  
o What proportion of those we inject should obtain immediate pain relief, based on the 
agreed definition, for us to conclude we have selected a population likely to benefit 
from facet joint injections? 
• Which variable(s) should be used for a priori sub-group analyses in the main trial? 
As noted earlier a ‘protocol’ for injection technique and best usual care, based on the evidence reviews 
was presented as a starting point for discussion in the evidence document. We briefly outline these 
here. 
Suggested study protocol for facet joint injection 
We describe here, as a starting point for discussion, the protocol for injecting facet joints that we have 
proposed to the funders.   
 
When they attend for injection the operator will make a brief clinical assessment to satisfy themselves 
that facet joint injections are appropriate. Consent for the procedure will be obtained and the current 
pre-injection risk management procedures of the participating study centres will be adhered to. The 
operator will then inject the facet joint(s). We anticipate injecting up to six facet joints in each individual 
(L3/L4, L4/L5; L5/S1) bilaterally. However, where, on clinical assessment, there is unilateral pain, or 
9 
© FIS Consensus Conference Report 14 February 2015   
The University of Warwick, Version 1   
involvement of only some levels the operator may choose to do unilateral injection, or be selective on 
levels injected. We anticipate that everyone should receive at least two injections. This pragmatic 
approach reflects what actually happens in NHS practice. This approach is consistent with that used in 
trials of other complex interventions for low back pain, e.g. manual therapy or a cognitive behavioural 
approach, where practitioners choose from a limited range of options based on their clinical assessment 
of the patient. 
Procedure to position the needle: 
 We do not anticipate using intravenous sedation. 
 Prone position with pillow under abdomen to flatten lumbar lordosis. 
 Intravenous access, resuscitation equipment available. 
 Skin cleansing with chlorhexidine 0.5% or 2% in alcohol, sterile drapes. (Some clinicians think 
that 2% chlorhexidine is neurotoxic and like to use 0.5% as skin cleansing before nerve blocks. 
On the other hand 2% chlorhexidine is recommended by the control-of-infection experts as 
optimum skin cleansing before intravenous cannulation and may be preferred in some Trusts). 
 X-ray imaging (C-arm fluoroscopy) oblique view to visualise joint. 
 The dose of radiation used will be adequate to visualise the joint while minimizing X-ray 
exposure. 
 Skin weal at needle entry point: 1% lidocaine via 25G hypodermic needle. 
 22G x 3.5 inch (0.7 x 90 mm) needle with Quincke type point guide to joint cleft. 
 Entry to the joint cleft may be indicated by X-ray appearance: observation of the needle tip on 
the joint line with medial/lateral movement of the X-ray beam to cause parallax shift. 
 If entry to the joint has not been achieved after repositioning the needle twice, the needle will 
be positioned on the joint line without further attempts at capsular puncture. 
 Aspiration should be negative for blood or cerebrospinal fluid. 
 We do not anticipate using contrast medium because of the restriction of available joint volume 
and the risk of serious allergic reactions. 
 The immediate post injection advice will be in accordance with the current procedures of the 
participating study centre. 
Injection: 
 Pre-filled syringes containing bupivacaine 7.5mg and methyl prednisolone 20mg in total volume; 
2ml will be used for each joint. 
 The full volume, 2ml, will be injected through the spinal needle placed into each joint. Some 
facet joints may not be sufficiently large to take this volume of injectate meaning in practice 
that the injections will be intra- and peri-articular. This reflects what we believe to be current 
practice in the UK. 
 Resistance to injection may occur due to abutment of the needle bevel to a surface or due to 
filling of the intra-articular space: 
o Force should not be used. 
o The needle should first be rotated 90° and a further attempt at injection made. 
o If, after two further 90° rotations resistance to injection persists or if, after successful 
injection of a part volume resistance develops, gentle pressure should be maintained on 
the plunger and the needle withdrawn gradually until resistance to injection falls. 
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After completion of the injection the needle is removed and a sterile dressing applied. 
Preliminary outline content and structure of ‘Best Usual Care’ package (the control intervention)  
Initial assessment 
Initial assessment of 60 minutes. Assessment includes discussion of expectations, fear avoidance and 
self-efficacy to assess any perceived challenges and barriers that patients feel may be preventing them 
from engaging in self-management of chronic pain and to allow subsequent treatment sessions to be 
tailed to individual need. For the intervention group, the facet joint injections are given in the period 
between this first assessment and the first follow-up appointment. 
 
Individual sessions 
Five further sessions each of 30-minutes incorporating elements of manual therapy, pacing, motor 
control retraining, therapeutic exercise, soft tissue stretches/release, postural and general advice, goal 
setting and challenging negative thoughts associated with physical activity and chronic low back pain as 
appropriate. 
 
Manual therapy (MT) intervention may include: 
 Passive accessory intervertebral movements; either central, unilateral applied to either the 
symptomatic level or the level adjacent depending on the severity and irritability.  
 Soft tissue release/trigger point release/muscle energy techniques as indicated in order to 
facilitate motor control retraining and effectiveness of manual therapy  
 Manipulation treatment as indicated.  
 Active exercise to increase mobility, improved motor control and core stability, improve overall 
strength and stretch any tight muscle groups. 
 Mobility techniques such as flexion in lying, pelvic tilt, side glides in standing and gym ball 
exercises. 
 Motor control retraining exercises (depending on individual assessments). This may include all 
muscles involved in core stabilising of the spine and also reducing activity in more superficial 
muscles that have been shown to become over active in the presence of LBP.  Treatment 
focuses on retraining the ‘co-activation’ pattern of stabilising muscles such as transversus 
abdominus and lumbar multifidus (LM). This includes retraining of lumbar multifidus as it is 
innervated by the medial branch and becomes inhibited ipsilateral to the pain in chronic back 
pain conditions. There is also evidence that specific retraining of ‘core muscles’ can improve 
pain and disability in some back pain patients. 
 Passive stretches. Muscle groups identified during assessment as tight or overactive may be 
stretched within the therapy sessions in order to allow for improved spinal mobility and 
facilitate motor control retraining. Stretches taught as part of the home exercise regime. 
 
Home exercises and advice may include: 
 Bespoke exercise programme to complement face to face sessions.  Prescription to include 
frequency, dose, repetitions and progressions.   
 Advice on positions of ease, strategies to use in event of a ‘flare-up’, and strategies to reduce 
increasing pain e.g. use of pelvic tilt prior to standing after prolonged sitting. 
 
Cognitive approaches may include:  
 Pacing including discussion of what is meant by pacing, relevance of pacing and methods to 
incorporate pacing into daily activities such as pacing by time, pacing by numbers or pacing by 
grading activities. 
 Goal setting, including discussion of setting mutually agreed goals related to functional activities 
as well general daily goals and long term goals. Goals agreed between the physiotherapist and 
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patient participant. In line with a CB approach, goals may be based on SMART principles; 
Specific, Measurable, Achievable, Realistic and have a Time frame (a date for competition).  
 Challenging negative automatic thoughts (cognitive restructuring) including, working with 
patients to identify particular negative thoughts they may have in relation to physical activity 
and fear avoidance, and helping patients challenge their thoughts and adapt positive coping 
strategies. 
 Homework tasks between each session tailored to each individual and what is discussed during 
the session. For example, using pacing on a particular activity identified by the patient, keeping 
a diary of negative automatic thoughts that may trigger anxieties about movement or exercise 
and pain. 
 
Conference: 
On the day of the conference 50 attended of the 57 who had confirmed attendance, Table 1. gives an 
overview of attendees.  
Table 1. Overview of those who attended the consensus conference  
Role  
Pain consultants and physicians  19 
Anaesthetists  6 
Physiotherapist or Physical specialists 12 
Academics 2 
Psychologists 3 
Radiographers 2 
Lay representatives 6 
 
Below we present the results from the morning small group sessions (using nominal group technique) 
for each of the design considerations. The results from these were taken forward to the afternoon 
plenary session. 
Diagnosis 
Table 2. gives an overview of all of the results from the four morning group sessions which were taken 
forward to the plenary session in the afternoon for discussion and consensus. Key components of a 
diagnostic assessment were discussed including increased pain on extension or rotation, rising from 
flexion and extension/lateral flexion; in addition, no radicular symptoms, no SI joint pain, and in a pain 
provocation test flexion less painful than extension. Consensus was not reached on the day, see post-
conference results below. 
The process of facet joint injection 
Table 3. gives an overview of the results from the four morning sessions and the plenary session in the 
afternoon. Delegates had 14 items to consider in this session covering all aspects of the process. Many 
of these were deemed to be ‘acceptable’ by the groups for use in practice and required no further 
discussion. Alternatives were suggested where there was disagreement and results taken to plenary 
session. Table 4. shows that much of the protocol for injection technique was agreed in this session. 
However, verifying the results post-conference several errors in rankings and votes were found these 
were resolved with email votes sent to delegates post-conference. The outcome of this is reported 
below. 
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Table 2. Group and Plenary Results from Facet injection Study Consensus Conference looking at: What is the best choice of clinical assessment to identify 
patients with suspected facet joint pain? 
Diagnosis group 1
Group generated list of 7 options:
a) Extension and Ipsilateral side 
bending (standing)
b) Extension and Ipsilateral 
rotation (prone)
c) Psychological distress
d) Para-Median tenderness
e) MRI Lumbar spine W. 
Hypertrophic facet joints or 
fluid
f) Personality inventory
g) Focal low back pain
The first round of ranking excluded: e & f
The top 5 were then ranked again:
Rank 1: G: Focal low back pain
Rank 2: A: Extension / Ipsilateral side 
bending (standing)
Rank 3: D. Para-Median tenderness
Rank 4: C. Psychological distress
Rank 5: B. Extension and Ipsilateral 
rotation (prone)
Diagnosis group 2
Group did not vote but agreed on a 
diagnostic pathway (outlined below).
HISTORY (in. absence of Red Flags)
 Gradual onset (usual)
 Lumbar sacral
 Localised (no pain below knee) 
 back pain predominant feature
 No neurological symptoms
 Relieved at rest
 Mechanical presentation
 Worse on weight bearing
 Worse on rotation and extension
 Functional activities
 Realistic expectations
 Clinical reasoning of psycho-social 
factors
 Absence of cough/sneeze/Valsalva 
symptoms
CLINICAL FINDINGS
 Active ROM extension, Ipsilateral sf, 
Ipsilateral rotation
 Combined movements 
 Pain on local palpation
 Absence of wide-spread hyper-
algaesia and analodynia
 No neural tensions signs
 Psycho-social screening tool
 Flexion not aggravating combined 
movement
 Pain 
Quality (aching)
On rising in morning
Variable
Non-neurologic
Diagnosis group 3
Group agreed a list of signs and symptoms:
Signs:
 Localised tenderness (para-spinal)
 Localised tenderness over joint
 No tenderness on sacroiliac joint 
palpation
 No pain provocation on straight leg 
raise (to exclude neural tension)
Symptoms:
 Pain increases on standing for long 
periods 
 Pain increases when  climbing stairs
 Pain increases on extension
 Pain increases on lateral rotation
 Pain decreases when lying down
 Pain decreases on flexion
 Can have radiation to back and thigh + 
buttocks but not below knee
 No pain radiating to groin
 Absence of Radicular symptoms and 
signs
 Time > 3 months
 Had course of physiotherapy that has 
not resolved back pain
Based on the list of signs and symptoms 
the group generated a further list that was 
ranked:
A. All signs listed plus all symptoms minus       
morning stiffness, time >3 months
B. As A. time > 1 year 
C. As A. time > 6 months 
D. As A. time > 1 year and unsuccessful 
course of physiotherapy
E. As A. time plus MRI
F. As D. time PLUS MRI
G. As A. plus diagnostic injection
After an initial ranking a further ranking 
produced a top three options:
Rank 1: (D), Rank 2 (A), Rank 3: (C). 
Diagnosis group 4
Group generated list of 18 items and votes 
were cast on acceptability:
A: Diagnostic injection (5 votes)
B: Pain increase on extension (7 votes)
C: Pain increase on twisting movement (3 
votes)
D: Pain increase on palpation (6 votes)
E: Pain increase extension and rotation (7 
F: Pain increase lateral flexion – towards 
painful side (6 votes)
G: No normal MRI/Radiological evidence4
H: Rising from flexion (7 votes)
I: No red flags (inc Radicular symptoms) (7 
votes)
J: No Sacro Iliac joint pain (pain 
provocation test) (7 votes)
K: Pain on standing (5 votes)
L: Pain on walking (3 votes)
M: Patients pain distribution para vertebral 
(6 votes)
N: Age > 35 (4 votes)
O: BMI > 40 (3 votes)
P: + Decrease in pain in opposite 
movements (3 votes)
Q: Extension and lateral flexion (7 votes)
R: Pain increase walking up or down hill
(4 votes)
Four groups were generated starting with 
all items with the highest acceptability 
score (which was 7) these were then 
ranked.
Rank 1: (Z)  X + D + M
Rank 2: (Y)  X + D
Rank 3: (W)  X + P
Rank 4: (X)  B + E + H + I + J + Q
Plenary discussions and outcomes Participants were asked the vote on the 
following being ‘acceptable’.
 1.       Increased pain unilaterally or 
bilaterally, on lumbar para-spinal palpation
AND
2.       Increased low back pain on one or 
more of the following; extension (more 
than flexion), rotation, extension/side 
flexion, extension/rotation AND  
Results groups sessions were combined 
and presented for discussion
The following option was discussed:
Increased pain on extension
Increased pain on rotation
3.       No radicular symptoms (defined as 
pain radiating below the knee) AND 
4.    No sacro-iliac joint pain elicited using 
a pain provocation test.
Question issued to  45   physios/scope 
practitioners/psychologists. Responses 
received:  23. Acceptable; YES = 22, NO = 1
Increased pain on rising from flexion
Increased pain on extension/lateral flexion
No radicular symptoms
No SI joint pain
Pain provocation test
There was no final vote on this item on the 
day. Consensus was reached Post-
conference; via email voting. 
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Table 3. Group and Plenary Results from Facet injection Study Consensus Conference looking at: What is the agreed technique for the injection of facet 
joints? 
Group 1. Injection Technique
There was consensus as per protocol for 
items: 1, 4, 5, 6, 7, 8 & 11
Item 2 was discussed as two from the 
group found the protocol not acceptable.
Following discussion, 3 Options ranked:
Rank 1: (A) As protocol
Rank 2: (B) As protocol but 8 joints not 6 as 
maximum
Rank 3: (C) As protocol ‘A’ but one of the 
joints must be L5/S1
Comments noted against item 2:
Interval between injections 3 – 6 minutes?
Two found items (3 & 9) not acceptable 
(there was no time for discussion on these)
Item 10 was discussed as a number in the 
group found protocol not acceptable.
Following discussion, 3 Options ranked:
Rank 1(X): As protocol
Rank 2(Z): Intermittent Fluoroscopy
Rank 3 (Y):Upper limit of radiation that is 
agreed locally
Item 11 was discussed as three in the 
group found protocol not acceptable.
Following discussion, 4 Options ranked:
Rank 1(D): As protocol but with 1ml Levo 
Bupivacaine
Rank 2(C): As protocol using  Levo 
Bupivacaine
Rank 3(B): 1ml instead of 2ml (same drugs)
Rank 4 (A): As protocol
Comments noted against item 11:
 Levo Bupivacaine (less cardio toxicity)
 2ml too high volume – 0.50 – 1ml 
Group 2. Injection Technique
There was consensus as per protocol for 
items: 3, 4, 5, 10, 11 & 14 – 9 after 
discussion
Item 1; As a result of discussion:
 Concern -> variation in study centres 
risk management... could affect 
outcomes
 Define brief Clinical assessment
Item 2; As a result of discussion:
 Up to 6
 Single injection possible (i.e. remove 
statement ‘we anticipate two 
injections...’
Item 6; as a result of discussion:
 Skin -> Weal
 Composition
 1% lidocaine
 Via 25g needle into skin
 + subcutaneous tissues at needle entry 
point 
 Rephrase; 1% lidocaine Via 25g needle 
into skin+ subcutaneous tissues at 
needle entry point
Item 7; As a result of discussion:
 22gauge 10 -15 cm Quinke needle 
(depending on body Habitus)
Item 8; As a result of discussion: Guide to 
joint cleft if possible intracapsular if not.
Item 12: As a result of discussion:
2ml per joint (some will be peri articular some 
intra articular)
Item 13; As a result of discussion:
 Methylprednisolone, 20mg 
 Bupivacaine, 7.5 mg
Group 3. Injection Technique
There was consensus as per protocol for 
items: 8, 10 & 11 after discussions items 1, 
3, 5, 7 & 14 were agreed as protocol.
Item 2 was discussed as two from the 
group found the protocol not acceptable.
Following discussion, 2 Options ranked:
Rank 1: (Y) As protocol + injection +/- 
Sacra... joint inject... if required
Rank 2: (X) As protocol 
Item 4 was discussed as two from the 
group found the protocol not acceptable.
Following discussion, 2 Options ranked:
Rank 1: (F) As protocol + Prone position 
with pillows for lordosis. Rank 2: (E) As 
protocol
Item 6 was discussed as three from the 
group found the protocol not acceptable.
Following discussion, 3 Options ranked:
Rank 1(Q): As protocol + Max 1ml per 
injection site. Rank 2(R): As protocol + Max 
0.5ml per injection site. Rank 3 (P): As 
protocol
Item 9 was discussed as two from the 
group found the protocol not acceptable.
Following discussion, 4 Options ranked:
Rank 1 (A): As protocol (parallax 
undefined). Rank 2 (D): As protocol but 
without parallax. Rank 3 (C):  As protocol 
but parallax intermittent. Rank 4 (B):  As 
protocol but parallax continuous
Item 12 was discussed as three from the 
group found the protocol not acceptable.
Following discussion, 4 Options ranked:
Rank1(P): 2ml (as protocol), Rank2(Q): 
1.5ml, Rank3(R): 1ml, Rank4(S): 0.5ml
Item 13 was discussed as four from the 
group found the protocol not acceptable.
Following discussion, 2 Options ranked:
Local anaesthetic: 2 options were ranked: 
Rank 1 (A): L –Bupivacaine, Rank 2 (B):  
Bupivacaine. Steriod: 2 options were 
ranked: Rank 1 (X): Triamcinolone, Rank 2 
(Y): Depo-Medrone (as protocol).
Sub question (Item 13):
2 options were ranked: Rank 1 (U):  As 
protocol with exclusion of systemic steroid 
use in last 3 months. Rank 2 (T):  As 
protocol
Group 4. Injection Technique
There was consensus as per protocol for 
items: 1, 3, 5, 6, 7, 8, 10 & 14. After 
discussions Items 2, 11, 12 & 13 were 
agreed as protocol.
Item 4 was discussed as one from the 
group found the protocol not acceptable.
Following discussion, 2 Options ranked:
Rank 1: (B) As protocol  plus measures to 
eliminate lumbar lordosis. Rank 2: (A) As 
protocol.
Item 9 was discussed as two from the 
group found the protocol not acceptable.
Following discussion, 2 Options ranked:
Rank 1: (X) As protocol 
Rank 2: (Y) As protocol but needle does not 
have to be oblique
Plenary discussions and outcomes
The 14 Injection topics open for 
discussion/agreement
1 Pre – injection consent/risk management
2 Processes used to select facet joints to 
be injected
3 Identification and visualisation of the 
selected joints 
4 Positioning of the patient
5 Skin cleansing/sterilisation methods/
materials
6 Administration of local anaesthetic/
composition
7 Gauge/type/length of needle
8 Method to approach joint 
9Methods used to confirm intra-articular 
positioning of needle
10 Dose of radiation
11 Optimal type/configuration of X-ray 
machine/equipment etc.
12 Injectate volume 
13 Injectate composition
14 After care advice
Groups voted on an item being 
‘acceptable’(i.e. not necessarily what they 
themselves would do or advise but an 
acceptable method/technique). 
Items with disagreements were discussed, 
alternatives suggested and voted/ on or 
ranked.
Results from the morning sessions were 
brought forward. Items: 1, 2, 3, 4, 5, 7, 8, 
10, 11 & 14 were briefly discussed but 
there was general consensus on these.
Item 6. was discussed 3 options were 
ranked: Rank 1(P): As protocol. Rank 2(Q): 
Max 1.0ml per injection site
Rank 3 (R): Max 0.5ml per injection site
Notes: 44 Ballots two of which were 
spoiled (total included 42)
Item 9. was discussed 3 0ptions were 
ranked: Rank 1 (A): As protocol. Rank 2 (C): 
As protocol adding intermittent Parallax. 
Rank 3 (D):  No Parallax (remove from 
protocol). Notes:  Adding continuous 
Parallax to protocol was discarded before 
ranking.
Item 12. 4 options ranked: Rank1 (P): 2ml 
per joint (as protocol). Rank2(R): 1ml. 
Rank3(Q): 1.5ml. Rank4(S): 0.5ml
Notes: 41 Ballots, one noted not qualified 
to respond. 15 participants did not rank all 
four items just giving their top one or two. 
Item 13. Local anaesthetic. Two options 
voted on ( Bupivacaine & lidocaine) both 
receive 6 votes.  
Item 12 cont. Steroid
2 options were voted on: Triamcinolone 
(18 votes). Depo-Medrone (as protocol)  (6 
votes). Either (12 votes)
Notes: There were 36 valid votes
A number of results were confirmed post 
conference see below.
 
14 
© FIS Consensus Conference Report 14 February 2015   
The University of Warwick, Version 1   
Table 4. Group and Plenary Results from Facet injection Study Consensus Conference looking at: What is the optimal conservative management/rehabilitation 
for patients with low back pain where facet joints have been identified as a contributing source of symptoms? 
Group 1, Best Usual Care package
Initial agreements: result of vote agreeing/
disagreeing with protocol items (yes = 
agree, no = disagree)
A. Initial assessment (5 yes, 4 no)
B. Individual session, number of sessions 
and duration (5 yes, 4 no)
C. Manual Therapy (6 yes, 3 no)
D. Home exercise (7 yes, 2 no)
E. Cognitive approaches (5 yes, 4 no)
Note: Individual (rather than group) 
sessions, the number of sessions in total 
(6), and the duration of each session; were 
combined in this group for the vote.
Group 2, Best Usual Care package
Initial agreements: result of vote agreeing/
disagreeing with protocol items (yes = 
agree, no = disagree)
A. Initial assessment (5 yes, 0 no)
B. Individual session, number of sessions 
and duration (8 yes, 1 no)
C. Manual Therapy (6yes, 3 no)
D. Home exercise (8 yes, 1 no)
E. Cognitive approaches (5 yes, 0 no)
Note: Individual (rather than group) 
sessions, the number of sessions in total 
(6), and the duration of each session; were 
combined in this group for the vote.
Group 3, Best Usual Care package
Initial agreements: result of vote agreeing/
disagreeing with protocol items (yes = 
agree, no = disagree)
A. Initial assessment (10 yes, 0 no)
B. Individual session and number of 
sessions  (8 yes, 2 no)
C. Duration of sessions
D. Manual Therapy (9 yes, 1 no)
E. Home exercise (10 yes, 0 no)
F. Cognitive approaches (10 yes, 0 no)
Note: Individual (rather than group) 
sessions, the number of sessions in total 
(6), were combined in this group for the 
vote. The duration of each session was 
voted alone. 
Group 4, Best Usual Care package
Initial agreements: result of vote agreeing/
disagreeing with protocol items (yes = 
agree, no = disagree)
A. Initial assessment (10 yes, 0 no)
B. Individual session and number of 
sessions (8 yes, 2 no)
C. Duration of sessions (6 yes, 4 no)
D. Manual Therapy (8 yes, 2 no)
E. Home exercise (7 yes, 3 no)
F. Cognitive approaches (8 yes, 2 no)
Note: Individual (rather than group) 
sessions, the number of sessions in total 
(6), were combined in this group for the 
vote. The duration of each session was 
voted alone. 
Plenary discussions and outcomes
Result of votes for additional/excluded  items in best usual care package Additional Items: Cognitive approaches
Acceptance ( 9 yes, 0 no)
Mindfulness ( 9 yes, 0 no)
Option of written/electronic information (9 
yes, 0 no) 
No additional cognitive approaches put 
forward by this group
No additional cognitive approaches put 
forward by this group
Pain education 
Advice on managing ‘flare up’ 
Mindfulness/relaxation sessions 
A unanimous yes vote for all
Result of votes for additional/excluded  items in best usual care package Additional Items: Physical Therapy
 A. Pain education (9 yes). B. manual 
movement assessment (7 yes). C. Activities 
of daily living (9 yes). D. Work /ergonomic 
advice (9 yes). E. Lifestyle changes (9 yes). 
F. Advice on changing symptoms (9 yes).
3 options were ranked
Rank 1: (X) 6 sessions 30/45 minutes over 6 
weeks to 6 months. Rank 2: (Y) 5 x 45 
minutes. Rank 3: (Z) As protocol
Addition of ‘paced’ to home exercise? (yes 
8). Removal of passive movements? (6 no). 
To include initial therapy? (10 yes)
4 options ranked (all sessions 30mins)
Rank 1: (X) SOS session 1 month after final 
session. Rank 2:(Z) As protocol. Rank 3: (Y) 
Until therapy is effective or inappropriate. 
Rank 4: (W) SOS session 3 months after 
final session
Home exercise (10 yes). Combined aerobic 
exercise and whole body strength 
conditioning (10 yes) Combined movement 
approach (6 yes, 2 no). Manual therapy (8 
yes)
3 options were ranked
Rank 1: (Z) As protocol. Rank 2: (Y) 1 X 45 
minutes followed by 5X 20 minutes. Rank 
3: 5X 60 minutes (including assessment) 
Positive/supportive therapist language (8 
yes). Addition of TENS (8 yes). Addition of 
acupuncture (6yes, 3 no)
5 options were ranked
Rank 1: (C) 2-10 sessions X 30 minutes. 
Rank 2:(E) As protocol but up to 5 sessions. 
Rank 3: (D) 2-4 hours of therapist contact 
time. Rank 4: (A) As protocol. Rank 5: (B) 
10X 60 minutes
Where possible top ranked or key results 
from the morning sessions were brought 
forward for discussion and consensus to 
the plenary session. However, a number of 
items included things  that were outside of 
the project brief (e.g. endpoint is 3-months 
so 6-months not feasible). These were 
mentioned and adjusted accordingly. 
The first discussions surrounded the 
possibility of including TENS and/or 
acupuncture in the package. A vote was 
taken to include then
Result:
TENS? (11 yes, 18 no)
Acupuncture (3 yes 38 no)  
7 options were discussed
The two below were dropped
5 sessions, 45 minutes each
10 x 1 hour sessions
5 options were ranked:
Rank 1: (X) Up to 6X 45 minute sessions for 
3 months
Rank 2:(E) As protocol but up to 5 sessions
Rank 3: (D) 2-4 hours of therapist contact 
time
Rank 4: (A) As protocol
Rank 5: (B) 10X 60 minutes
Final result for BUC package was confirmed 
post-conference. 
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Best usual care package 
Table 4. presents the results from the four morning sessions leading to the afternoon plenary 
session. The morning sessions discussed the acceptability of the proposed protocol items and 
additions, both cognitive and physical, were discussed and voted on. Comprehensive packages were 
proposed in all groups and these were taken forward to the afternoon plenary session. Whilst a 
result was reached some clarification was sought post-conference (see below). 
Size of Signal 
Table 5. below summaries the results of the discussions. Note, there was considerable discussion in 
these groups and some questions were not covered due to time constraints. 
Table 5. Summary of results from the morning small group discussions related to: ‘What is the 
difference in magnitude of response between treatment and control groups that should be 
considered large enough to establish the scientific or therapeutic importance of the results?’ 
Q 1.1. At 3-months, should we be seeking a mean between-group difference in change scores that is 
smaller / the same / or larger than that observed for the trials of manual therapy? 
  Group 1 (total votes) Group 2 (total votes) 
A Smaller 1 0 
B Larger 6 9 
C Same 2 2 
    
Q 1.1a. Additional question asked in group 1: Should we be asking the number that got 
better/difference in benefit?   
  Group 1 (total votes)  
A Smaller 2 NA 
B Larger 4 NA 
C Same 3 NA 
    
Q 1.2. Informed by the MID-units calculated for the trials of manual therapy (supporting evidence), 
at 3-months should we be seeking a small (<0.5), medium (0.5-1.0) or large (>1.0) MID-unit as proof 
of important difference? 
  Group 1 (total votes) Group 2 (total votes) 
A Small (< 0.5) 8 2 
B Med  (0.5-1.0) 1 5 
C Larger (> 1.0) 0 1 
    
Q 1.3. What magnitude of reduction in pain after the injection constitutes immediate pain relief? 
Group 1 discussions generated the four suggestions below. They then ranked them in order of 
preference. 
  Group 1 (Ranking)  
A 80% 2nd  
B > 50% 4th  
C 0% 3rd  
D 60% 1st  
 
Results from the morning sessions were brought forward to the afternoon plenary session where 
there was a considerable amount of discussion about this topic. As there was a difference of opinion 
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from the morning session for question 1.2 the whole group were asked to vote on the two items, A. 
Small (< 0.5) and B. Med (0.5-1.0). There were 48/49 valid votes with the outcome: 
• Small (<0.5) – 8 votes 
• Medium (0.5-1.0) – 40 votes 
An additional question was posed: ‘What difference in those who achieve minimally important 
change (MIC) is good? The group were asked to vote on three options: Larger, same and smaller. 
44/49 ballots were valid with the result being:  
 Larger – 22 votes 
 Same – 9 votes 
 Smaller – 13 votes 
During discussion it was raised about the study measuring pain relief at one hour. A vote asking 
‘should we assess pain at one hour? The result was inconclusive with a total of 46 valid votes: 22 
saying yes and 24 saying no. 
Finally, the group revisited question 1.3. What magnitude of reduction in pain after the injection 
constitutes immediate pain relief? (see table 6 above). Four options were suggested (some extracted 
from the morning session) and 46/48 valid votes were included (see items/result below). 
 30% - 4 votes 
 50% - 22 votes 
 60% - 12 votes 
 80% - 8 votes 
Sub Group Analysis 
There was one group discussion on this topic. Participants were presented with current evidence 
and asked to consider the variables they felt were important. Lists were generated and items 
collapsed into categories.  This resulted in a list of 10 variables. These were then ranked in order of 
importance. 
Table 6. below summarises the result from this group. 
Table 6.  Showing the final variables and order after ranking  
Final rank ID Variables 
1st A Severity 
2nd D Anxiety/depression 
3rd M Do you think you need an injection to get better 
4th E Treatment expectations 
5th H Back beliefs 
6th G QOL 
7th B Age 
8th F Self-efficacy 
=9th L Forward flexion pain y/n 
=9th N Does the therapist think the treatment is effective 
 
The top five ranked items were presented to the plenary for information. 
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Post-conference: 
Post- conference all voting and rankings from the day was checked and verified. A number of errors 
were noted in three of the design considerations (diagnosis, the process of facet joint injection and 
the best usual care package). 
Diagnosis 
In order to confirm the diagnostic criteria for the study 45 of the professional delegates were 
emailed to ask the following question: 
We would like you to review the following text and confirm if the suggested clinical 
diagnostic criteria proposed for the study is ‘acceptable’? Stating ‘YES’ or ‘NO’.   
Increased pain unilaterally or bilaterally, on lumbar para-spinal palpation. AND. Increased 
low back pain on one or more of the following; Extension (more than flexion), Rotation, 
extension/side flexion, extension/rotation. AND. No radicular symptoms (defined as pain 
radiating below the knee). AND. No sacro-iliac joint pain elicited using a pain provocation 
test.  
Responses received:  23, Acceptable: YES = 22, NO = 1 
 
The process of facet joint injection 
 
Following the consensus conference there was uncertainty about the injectate to be used in the 
study. Six options were sent, via email, to 27   pain consultants/anaesthetists/professionals 
(delegates) who indicated they were responsible for injection. We received 11 responses; the results 
can be seen in Table 7 below. 
 
Table 7. Results from email ballot of delegates to confirm injectate composition  
Injectate options Preferred (enter X )  
= n 
Acceptable (enter yes or no) 
= n 
Triamcinolone 10mg/ Levobupivacaine  
2.5mg 
4 Y = 5 
N= 2 
Triamcinolone 10mg/ Levobupivacaine  
5.0mg 
4 Y = 5 
N = 0 
Triamcinolone 10mg/ Levobupivacaine  
7.5mg 
1 Y = 6 
N= 3 
Triamcinolone 20mg/ Levobupivacaine  
3.75mg 
1 Y = 3 
N= 5 
Triamcinolone 20mg/ Levobupivacaine  
7.5mg 
0 Y = 4 
N= 4 
Triamcinolone 20mg/ Levobupivacaine  
11.25mg 
0 Y = 2 
N= 6 
 
Best Usual care package 
 
Confirmation of the number and duration of sessions was sought post-conference.  We emailed 15 
delegates who were physiotherapists, extended scope practitioners or clinical/health psychologists. 
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Two alternatives, a) and b) below, were sent and delegates were asked to state a preferred option 
and to also say if they felt it was acceptable or not. 
There were 12 responses. 
a) 1 session of 60 minutes plus 5 sessions of 30 minutes (9 preferred, 7 yes, 0 no)  
b) Up to six sessions of 45 mins each (3 preferred, 6 yes, 1 no) 
 
Among the 12 responses reported above, two responders answered both options were acceptable, 
one responder only provided a preference and did not state whether the options were acceptable 
and two responders preferred option a) and that this was the acceptable option. 
 
Dissenting voices 
Almost all delegates were very positive about the day. However, three delegates in total asked for 
their names to be removed from the Consensus group. Table 8. below gives the feedback we were 
given by these delegates 
 
Table 8.Feedback from delegates who requested being removed from any publication resulting 
from the conference.  
 
I took issue with several aspects of the consensus process, not least: the groups included lay 
members of public were asked to vote on highly technical decisions such as facet joint injection 
volume; and by the end of a long day, it felt like people (including clinicians) were being cajoled 
into voting for the sake of it whilst clearly not comprehending some of the decisions to do with 
statistics and study design. I felt that this whole process was exploiting evidence based medicine 
by trying to ensure not that the study would provide truth, but rather than it would garner wide 
agreement that there is indeed a legitimate role for facet joint injections, when the clinical 
evidence to date and the experience of several attending group members on the day make it clear 
that the benefit of injections is likely placebo. I do hope that the study adequately captures data 
on patient beliefs and expectations of both the treatment and clinicians, as was suggested in 
group sessions, because the placebo effect cannot be reliably detected by placebo control alone.  
[Delegate 1] 
 
Not agree on protocol 
1. Different physio methods at different sessions as best usual care package in the study – 
needs standardising for study after assessment  
2. Omit immediate assessment and 3 months to long for first assessment 
3. PROM > RMDQ & NRS – not adequate or representative  
4. 2 ml too much & 120mg Depo max dose too high 
5. Standardise physio sessions 
[Delegate 2] 
 
I do not have a disagreement. I am unsure about statistics. Hence kindly exclude my name from 
publication 
[Delegate 3] 
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Conclusions 
We have established consensus from health professionals concerned with the treatment of facet 
joint pain in the UK on the assessment of facet joint pain, injection of facet joints, best usual care, 
minimal important difference and subgroup analysis for use in a feasibility study for a proposed 
clinical trial of facet joint injections. The process was evidence based and open to all those with a 
professional interest in this topic. It included lay participants and was undertaken in a transparent 
way. The use or not of facet joint injection is controversial internationally so consensus and 
transparency is essential for the design of the proposed trial of facet joint injections to ensure the 
results are acceptable to the whole pain treatment community. 
 
Below we outline the areas where changes have been made to protocol as a result of the 
conference. A full protocol is available on the studies HTA webpages 
http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0019/130654/PRO-11-31-01.pdf 
 
Diagnosis 
Prior to the conference we had little or no clear protocol for the diagnosis of possible facet joint 
pain. The consensus has guided us towards a set of procedures that can be reproduced across 
practitioners, centres and is achievable in an NHS setting. 
 
Table 9. Diagnostic criteria for study 
1.       Increased pain unilaterally or bilaterally, on lumbar para-spinal palpation 
AND  
2.       Increased low back pain on one or more of the following; 
 extension (more than flexion) 
 rotation  
 extension/side flexion*  
 extension/rotation* 
AND  
3.      No radicular symptoms (defined as pain radiating below the knee or 
objective neurological signs above the knee#) 
AND  
4.    No sacro-iliac joint pain elicited using a pain provocation test.  
*Both tests representative of regular compression patterns (Edwards, 1999) 
# using a ‘contracted’ neurological examination (McCarthy, 2010) 
 
The process of injection 
Below we outline the injection procedure. The consensus conference covered all areas of this and 
whilst a suggested protocol was produced as a starting point for discussion the current protocol was 
shaped by the conference. Key changes included the steroid being injected, how the radiological 
monitoring was managed and the volumes of all injectates.  
The IMP will be 1ml of Levobupivacaine 5.0 mg/ml and 1ml of Triamcinolone 10mg/ml prepared 
within the same syringe will be used for each facet joint injection procedure. Preparation of the 
injection will be undertaken by the operator immediately prior to the injection. A total volume of 
2ml will be injected through the spinal needle placed into each joint. Some facet joints may not be 
sufficiently large to take this volume of injectate meaning in practice that the injections will be intra- 
and peri-articular. This approach of mixing such drugs immediately prior to facet joint injection is 
standard practice for this procedure within the NHS.  
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When the participant attends for injection, the operator will make a brief clinical assessment to 
satisfy themselves that facet joint injections remain appropriate. Consent for the procedure will be 
obtained and the current pre-injection risk management procedures of the participating study 
centres will be adhered to. The operator will then inject the facet joint(s). Up to six facet joints in 
each individual (L3/L4, L4/L5; L5/S1) bilaterally.  
Procedure to position the needle: 
 No intravenous sedation required. 
 Prone position with measures to reduce the lumbar lordosis,  e.g. a pillow under the 
abdomen. 
 Intravenous access, resuscitation equipment available. 
 Skin cleansing with chlorhexidine 0.5% or 2% in alcohol, sterile drapes.  
 X-ray imaging (C-arm fluoroscopy or other suitable equipment) to visualise joint. The dose of 
radiation used will be adequate to visualise the joint while minimizing X-ray exposure.   
 Contrast medium will not be used. 
 Local anaesthesia at needle entry point: 1% lidocaine via 25G hypodermic needle. 
 22G (0.7mm) needle with Quincke type point guided to joint cleft. 
 Entry to the joint cleft may be indicated by X-ray appearance.  Medial/lateral movement of 
the X-ray beam with intermittent screening  to cause parallax shift may be used. 
 If entry to the joint has not been achieved after repositioning the needle twice, the needle 
will be positioned on the joint line without further attempts at capsular puncture. 
 Aspiration should be negative for blood or cerebrospinal fluid. 
 The immediate post injection advice will be in accordance with the current procedures of 
the participating study centre. 
Injection 
 The operator will prepare the injection syringe to contain 1 ml of levobupivacaine 5.0mg and 
1ml Triamcinolone 10mg in total volume; 2ml will be used for each joint.  
 The full volume, 2ml, will be injected through the spinal needle placed into each joint. Some 
facet joints may not be sufficiently large to take this volume of injectate meaning in practice 
that the injections will be intra- and peri-articular. This reflects what we believe to be 
current practice in the UK. 
 Resistance to injection may occur due to abutment of the needle bevel to a surface or due to 
filling of the intra-articular space: 
o Force should not be used. 
o The needle should first be rotated 90° and a further attempt at injection made. 
o If, after two further 90° rotations resistance to injection persists or if, after 
successful injection of a part volume resistance develops, gentle pressure should be 
maintained on the plunger and the needle withdrawn gradually until resistance to 
injection falls. 
 After completion of the injection the needle is removed and a sterile dressing applied. 
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Best Usual Care Package (control Intervention) 
Below we summarise the best usual care package. The consensus process has informed many 
aspects of this package. The package is, in simple terms, a toolkit of physical and psychological 
exercises/approaches which the therapist can use to provide a bespoke treatment programme to 
people with possible facet joint pain. 
Session 1 – Assessment and planning (1 hour) 
Patients initially undergo a thorough physical assessment based on the principles of Maitland 
manual therapy assessment and clinical reasoning2. Symptomatic levels are identified and the 
severity and nature of the symptoms recorded and used to direct treatment.  
Assessment includes discussion of expectations, fear avoidance and self-efficacy to assess any 
perceived challenges and barriers that patients feel may be preventing them from engaging in self-
management of chronic pain and to allow subsequent treatment sessions to be tailored to individual 
need.  
Session 2 to 6 (30 minutes each) 
The aim of best usual care for this study is to provide a fully integrated psychological and physical 
rehabilitation.  It is important therefore to integrate the two elements of care as far as possible so 
that participants do not see them as ‘stand-alone’.    
Treatment should be directed at pain arising from the facet joint.  Physiotherapists should use their 
full range of skills and knowledge in constructing a personalised rehabilitation programme using the 
comprehensive ‘tool kit’ provided.  Certain elements of the ‘tool kit’ must be incorporated within the 
individualised programme and these must be recorded.  
Table 10 below gives an overview of the different physical and psychological components of the 
package.   
 
Table 10. An overview of components of the Best Usual Care package 
‘toolkit’.  
 
Table 10. An overview of components of the Best Usual Care package 
‘toolkit’.  
Modality/technique 
☐Acceptance (Session 1) 
☐Goal setting (Session 1 or 2) 
☐Pacing  (Session 1 or 2) 
☐Challenging negative thoughts  
☐Mindfulness 
☐Manual therapy  
 Kaltenborn 
 McKenzie 
 Maitland 
 Cyriax 
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 Osteopathic techniques 
 Mulligans 
 (NAGS/SNAGS/MWM) 
 Other 
☐Exercises (Session 1 or 2) 
 Specific  
 Motor control retraining/core stability 
 Cardiovascular 
 Strength 
 Stretches 
 Other 
☐Soft tissue 
 Myo-fascial 
 Trigger point 
 Soft tissue massage 
 Manipulation 
 Soft tissue release 
 Other 
☐Advice 
 Pain terminology, mechanisms and pathways 
 Activities of Daily Living  
 Work and ergonomics  
 Lifestyle changes 
 Management of flare ups & changing symptoms 
 Paced home exercises  
 Other 
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